Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $619
Benzinga Newsdesk 21 hours ago
Analyst RatingsNewsPrice TargetHot
Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $595 to $619.
Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $595 to $619.